Teva Pharmaceuticals Agrees To $85 Million Settlement With Oklahoma In Opioid Case | KPBS Public Media
Why Is Teva Pharmaceuticals (TEVA) Stock Up Today? | InvestorPlace
Teva Restructuring Coming Together, Rebuilding Confidence in the Company | BioSpace
Jerusalem, Israel. 21st Oct, 2019. The Teva Pharmaceutical logo is seen in English and Hebrew at their tablet production plant in Jerusalem, on Monday, October 21, 2019. The Israeli drug manufacturer Teva's shares have plummeted in recent months over ...
Teva Pharmaceutics USA acquires three buildings for an R&D campus in West Chester - Philadelphia Business Journal
Teva | Partnership | Direct Relief
Teva Pharm Expects About 25 Percent of EpiPen Market by Year End
Articles about Teva Pharmaceuticals, Inc.
Teva shares surge after announcing global opioid settlement
Teva boss hits out at opioid lawsuits
Teva Forecasts Growth After Expected Actavis Deal Closes | Stock News & Stock Market Analysis - IBD
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session | Markets Insider
Teva Faces New Class Action—But Could It Afford Another Se...
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Teva Pharmaceutical Industries – The Forward
Israeli drugmaker Teva to cut quarter of global work force (Update)
Teva to pay New York $500M for role in opioid crisis - POLITICO
Teva Pharmaceutical | PBS NewsHour
Teva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook Warning - WSJ
Teva shares surge after announcing global opioid settlement
Teva Reaches Tentative $4.25 Billion Settlement Over Opioids - The New York Times
Teva Pharmaceuticals at heart of major price fixing suit in US – www.israelhayom.com
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Helsinn Healthcare v. Teva USA (Decision January 22, 2019) | Subscript Law
Teva CEO: Company Would Have Gone Bankrupt Without Layoffs - Business - Haaretz.com
Teva taps new CFO, hikes legal set-aside to more than $1B as opioid deal falters | Fierce Pharma
